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Abstract
Background: Solidago chilensis (syn. microglossa) is a plant from the Asteraceae family widely distributed in South
America and used to treat inflammatory diseases. In 2009, it was listed as one of the native medicinal herbal plants
used in the Brazilian public health system. In addition to its anti-inflammatory properties, a recent clinical study has
shown antinociceptive effects of S. chilensis, introducing a new potential medical use for this plant. The aim of the
present study was to investigate the antinociceptive activity of the hydroalcoholic extract of Solidago chilensis
(HESc) in rodent models of pain.
Methods: The dried plant extract was obtained from its aerial parts, maintained in ethanol (100 g/l) and filtered.
Rats or mice were treated with intraperitoneal injections of HESc (3, 10 or 30mg/kg) 30min before being submitted to
writhing, 0.2%-formaline or hot-plate tests or prostaglandin E2 (PGE2) administration in the hind paw. Mechanical
hypernociception and motor impairment were evaluated by electronic von Frey and rota-rod, respectively.
Results: HESc dose-dependently inhibited abdominal contortions in the writhing test and attenuated phases I and II
formalin-induced nociceptive behavior. Treatment with HESc also increased thermal threshold and decreased PGE2-
induced hypernociception without promoting motor impairment.
Conclusions: Our data suggest that, when systemically administered, HESc decreases nociception without inducing a
sedative effect. Importantly, this effect was observed in both inflammatory and non-inflammatory models of pain and
nociception, suggesting a specific non-inflammatory mechanism of HESc on pain. Our findings indicate that S. chilensis
might be an important adjuvant in pain management.
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Background
The genus Solidago is considered one of the largest gen-
era of the Asteraceae family of plants, comprising more
than 120 species, most of which are found in North and
South America [1]. This genus comprises a great num-
ber of medicinal plants with therapeutic properties.
Among them, S. chilensis Meyer (syn. microglossa) has
been recently considered for the treatment of inflamma-
tory diseases. Studies have demonstrated that aqueous
or hydroalcoholic extracts of S. chilensis or its essential
oil contain compounds with relevant anti-inflammatory
activity similar to those of dexamethasone [2–4].
In Brazil, where the plant is wildly found, the extract
of S. chilensis is currently indicated as a therapeutic tool
for contusion, trauma and boils by Medicinal Plant Pro-
grams [5]. Since 2009, S. microglossa was included in the
national list of native medicinal plants used by the Bra-
zilian public health system (SUS). S. chilensis is used
topically or by oral administration, depending on the re-
gion and according to cultural traditions. Patches from
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leaves and stems are used for muscle pain or skin lesions
[6, 7]. Infusion, bath, decoction or tincture of S. chilensis
flowers or the whole plant macerated are also used for
wound healings and boils, purulent infections, inflam-
mation, edema, body pain, chill or rheumatism [8–10].
In light of its traditional medical use, pre-clinical stud-
ies in rodents have investigated the therapeutic effects of
S. chilensis for a variety of conditions, with encouraging
results. S. chilensis has been shown to exert antifungal
activity in in vitro assays [11, 12]. The plant also induces
gastroprotective activity in rodents [13, 14], and amelio-
rates insulin resistance in obese mice [15]. Of note, pre-
vious studies in rodents have also shown that S. chilensis
exerts an anti-inflammatory modulatory role in murine
models of pleurisy [2], air pouch [3], and ear oedema
[4]. Based on its anti-inflammatory properties in animal
models and its traditional medical use, clinical trials have
recently investigated the potential analgesic effects of S.
chilensis extract in humans. Volunteers with lumbago
[16] and tendinitis of flexor and extensor tendons of
wrist and hand [17] were locally treated with topical gel
containing S. chilensis extract. In both studies, patients
reported significant reduction in the perception of pain
compared to placebo. Although those studies included
small sample sizes (20 and 8 participants, respectively),
they introduce a new field of investigation on S. chilensis
that might have important clinical implications for pain
management.
The aim of the present study was to verify whether the ex-
tract of S. chilensis exerts antinociceptive and anti-hyperno-
ciceptive effects in different experimental models in rodents.
Because of the proven anti-inflammatory action of this plant,
we investigated the effects of a hydroalcoholic extract of S.
chilensis in models of inflammatory pain, including the
writhing test and the formalin test. In order to test if S. chi-
lensis also exerts significant effects on the central transmis-
sion of pain, we investigated the effects of its extract in
models of non-inflammatory pain, such as nociceptive re-
sponse to heat or a mechanical stimulus.
Methods
Botanical material
Solidago chilensis Meyen (plant name checked with
http://www.theplantlist.org) was collected in the city of
Guararema, São Paulo, Brazil. Botanical identification and
authentication were performed by Dr. Lucia Rossi from
the Instituto Botânico de São Paulo, São Paulo, Brazil, and
one specimen was deposited in the herbarium under the
number SP 397.047. The aerial parts of the plant (flowers,
leaves and stalks) were used in the extract.
Hydroalcoholic extract of Solidago chilensis (HESc)
The aerial parts of the plant were immersed in 93%
ethanol (100 g/l) for one month. After this period, the
hydroalcoholic extract was filtered, concentrated using a
rotary evaporator and then lyophilized. The dried mater-
ial was stored at 4 °C until use. The dried extract was di-
luted in saline immediately prior to use. Solutions were
given intraperitoneally (i.p.) at a volume of 10 ml/kg of
body weight.
The chemical characterization of the HESc employed in
the present study has been described in a previous study
from our group using the same extract [4]. Analysis via
HPLC–DAD–MS and HPLC–MS/MS employing the ana-
lytical methodology developed by Gobbo-Neto and Lopes
[18] demonstrated that chromatograms obtained for the
hydroalcoholic extract presented 4 main peaks, that were
identified as 5-O-E-, 3,4-, and 4,5-di-OE-caffeoylquinic
acids and rutin.
Animals
Male 3-month-old Swiss mice (25–35 g) and Wistar rats
(200–250 g) were obtained from the vivarium of the
University of São Paulo/Ribeirão Preto or the Braz
Cubas University. Animals were group housed in poly-
propylene cages (5–7 per cage for mice; 3–4 per cage for
rats) under controlled temperature (22 ± 1 °C) in a light/
dark cycle of 12 h (lights on at 7:00 am) with free access
to food (chow) and water. All protocols and animal care
and handling strictly followed the National Institutes of
Health Guide for the Care and Use of Laboratory Ani-
mals (8th edition, revised 2011), and animals were main-
tained in accordance with the Brazilian Law for
Procedures for Animal Scientific Use (#11794/2008). All
animals were naïve prior to the beginning of the study.
At the end of the study, animals were submitted to 35%
CO2 euthanasia. All experimental procedures were ap-
proved by the Institutional Ethical Committee from Braz
Cubas University (protocol #175/2008) and University of
São Paulo/Ribeirão Preto (protocol # 11794/2008).
Experimental procedures
All experiments were performed during the same time of
day (8 am-12 pm). The doses and route of administration
(intraperitoneal) used were chosen based on previous stud-
ies from our group investigating the effects of HESc on
acute inflammation [4]. In our previous study, only topical
and intraperitoneal, but not oral, administration of the ex-
tract exerted anti-inflammatory effects in rat ear oedema,
suggesting that the absorption of its anti-inflammatory
component(s) may be affected by the gastrointestinal tract
[4]. For all experiments described below, animals were ran-
domly assigned to different experimental groups. Animals
were randomly selected from each cage of group-housed
animals, and a random component (referring to a random
number on a pre-designed table) was used in order to as-
sign the animals to their specific groups and/or treatment
allocations. The order of animals being submitted to the
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behavioral tasks was arranged so that animals from differ-
ent groups were being tested either at the same time or
consecutively. One experimenter, who was not blinded,
was assigned the task of administering treatments and dis-
tributing animals throughout an experiment. All observers
scoring behavior and performing data analysis were
blinded to treatment allocation.
Writhing test
The writhing test was performed as previously described
[19]. Writhing behavior was induced by i.p. injection of
0.4 ml of acetic acid (0.6%) diluted in distilled water.
Four groups of 6 mice each were pre-treated with i.p. in-
jection of saline or HESc (3, 10 or 30mg/kg) 30 min be-
fore acetic acid administration. Immediately after acetic
acid injections, mice were placed in individual glass
tanks and the number of cumulative writhing behaviors
was measured over 15 min.
Formalin test
The formalin test was performed as previously described
[20]. Five groups of 6 rats each were treated with i.p. in-
jection of saline (Sal) or HESc (3, 10 or 30mg/kg) 30
min before the administration of saline (Sal-Sal group)
or 20 μl of 0.2% formalin (Sal-, HESc3-, HESc10- and
HESc30-Formalin groups) on the plantar surface of the
right hind paw. After formalin injection, rats were im-
mediately placed in an open-field arena for the evalu-
ation of nociceptive behavior according to the following
score: 0, normal posture; 1, injected paw on the ground
but not supporting the animal; 2, injected paw clearly
raised; 3, injected paw being licked, nibbled, or shaken.
The different parameters were timed every minute dur-
ing the first 5 min and every 5 min afterwards in a 50
min session. The nociception index was determined by
the mean of the pain score for each group.
Hot plate test
The hot plate test was performed as previously described
[21]. The thermal stimulation of the hot-plate apparatus
(10 cm wide glass cylinder on a hot plate - IITC Life Sci-
ence Inc. CA, USA) was maintained at 55 ± 1 °C. Mice
were placed on the heated surface and the latency to
jump or licking response was measured. Two control la-
tencies at least 10 min apart were determined for each
mouse. Animals were removed from the apparatus right
after the expression of nociceptive behavior. A latency
period of 30s was defined as complete antinociception
(cut-off ). Four groups of 5 mice each were treated with
i.p. injection of saline or HESc (3, 10 or 30mg/kg) 30
min before being placed in the apparatus and the ther-
mal latency was evaluated every 30min during 240 min.
Hypernociception test
The test consisted in evoking a hind paw flexion reflex
with a hand-held force transducer adapted with a
0.7-mm2 polypropylene tip (Electronic von Frey; IITC
Life Science, Woodland Hills, CA). The investigator was
trained to apply the tip perpendicular to the central area
of the hindpaw with a gradual increase in pressure. The
end-point was characterized by the removal of the paw
followed by clear flinching movements. After paw with-
drawal, the intensity of the pressure was automatically
recorded, and the final value for the response was ob-
tained by averaging three measurements (basal mechan-
ical nociceptive threshold). After collection of basal
measures, 5 groups of 5 rats each were treated with i.p.
injection of saline (Sal) or HESc (3, 10 or 30 mg/kg) 150
min after the administration of saline (Sal-Sal group) or
prostaglandin E2 (PGE2, 100 ng/paw; Sal-, HESc3-,
HESc10- and HESc30-PGE2 groups) in the plantar sur-
face of right hind paw. After Sal or HESc injection, rats
were immediately placed in acrylic cages (12 × 20 × 17
cm) with wire grid floors for evaluation of nociceptive
behavior. The mechanical nociceptive threshold was
evaluated by crescent pressure in the rat paw 30, 60 and
90min after Sal or HESc treatment. Hypernociception
was calculated as the difference between basal and
post-treatment mechanical nociceptive thresholds (Δ).
Rota-rod test
To rule out possible nonspecific muscle-relaxant or
sedative effects of HESc, mice were tested in the
rota-rod apparatus, as previously described [21].
Twenty-four hours before the test session, all animals
were observed in the rota-rod apparatus. Only mice that
remained in the bar for 2 consecutive periods of 60s
were considered for the test on the following day. Five
groups of 6 mice each were treated with i.p. injection of
saline, HESc (3, 10 or 30 mg/kg), or 2 mg/kg diazepam.
Results are expressed as the time that the animals
remained on the rota-rod in a 60s session in 4 different
time-points: before treatment (basal) and 30, 60 and 90
min after the injections.
Statistical analysis
Sample sizes were calculated using the freely download-
able software G Power for sample size calculation and
performing an a priori analysis. The sample size was cal-
culated using the power analyses for analyses of variance
for fixed effects, using a one-factorial design (Experi-
ment 1) or a multi-factorial design (Experiments 2 to 5).
We have assumed a significance level (alpha) of 5% for
all experiments, and power (probability of finding an ef-
fect) of 80%, using a two tailed test, with no expected at-
trition. Before conducting the statistical analysis, all
variables were checked for normality (Shapiro–Wilk
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test) and homogeneity (Levene’s test), which validated
the use of the parametric tests. Grouped data were ana-
lysed by one- or two-way analysis of variance (ANOVA)
with repeated measures when appropriate followed by
Bonferroni post hoc tests. For conditions in which re-
peated measures ANOVA was used, all variables were
checked for and passed sphericity test. Using a two-way
ANOVA allowed for the evaluation of a possible inter-
action effect between two given variables (variables de-
scribed in the Results description of each Experiment).
Whenever an interaction effect was observed, that ef-
fects was described in the results section. All graphical
data presentations were created using Prism 5 (Graph-
Pad Software), and all statistical tests were performed
using PASW Statistics 18 (SPSS Statistics Software). A p




One-way ANOVA indicated a significant difference be-
tween groups [F(3,20) = 29.88, p < 0.0001] (n = 6 per
group, 4 groups). Bonferroni post-hoc test indicated that
the group treated with 3 mg/kg HESc showed no signifi-
cant difference when compared to the saline control
group. However, higher doses of HESc (10 or 30mg/kg)
were significantly effective in reducing the number of
writhes compared to both control and HESc 3mg/kg
groups (Fig. 1).
Formalin test
Fig. 2 represents the effects of intraperitoneal adminis-
tration of HESc (3, 10 or 30mg/kg) on the acute (0-5
min, Fig. 2a) or inflammatory (15-50 min, Fig. 2b) phases
of the formalin test session. Factors compared in the
two-way repeated measures ANOVA were time (minutes
0–5 or 15–50), pre-treatment condition (saline vs HESc)
and their interaction. In the acute phase, two-way
repeated measures ANOVA indicated a significant effect
of pre-treatment condition (Sal vs HESc3, HESc10 or
HESc30) [F (4,125) = 21.88; p < 0.0001] (n = 6 per group,
5 groups). As expected, Bonferroni post hoc test indi-
cated that formalin administration (Sal-Formalin group)
enhanced nociception indexes at all time-points com-
pared to Sal-Sal group, an effect was significantly re-
duced by previous administration of 3 mg/kg HESc.
Moreover, 10 and 30 mg/kg HESc decreased nociception
indexes during the entire acute phase of the test com-
pared to Sal-Formalin group, showing the effect of the
extract on acute nociception (Fig. 2a).
During the inflammatory phase, two-way repeated
measures ANOVA indicated a significant interaction be-
tween time and pre-treatment factors [F (28,175) = 8.76;
p < 0.0001]. Bonferroni post hoc test indicated that all
doses of HESc were effective in reducing, either attenu-
ating (3 mg/kg) or abolishing (10 and 30mg/kg),
formalin-induced enhanced nociception index (Fig. 2b).
Hot plate test
Factors used in the two-way repeated measures ANOVA
were time (minutes 0–240), pre-treatment condition (sa-
line vs HESc) and their interaction. Two-way repeated
measures ANOVA indicated a significant interaction ef-
fect between time and pre-treatment (Sal vs HESc3,
HESc10 or HESc30) factors [F(24,128) = 19.50; p =
0.0001] (n = 5 per group, 4 groups). HESc pre-treatment
significantly enhanced the latency to response to thermal
stimulus compared to control (Sal) condition, effect that
was dissipated across time (Fig. 3). Bonferroni post hoc
test indicated that the group treated with 3 mg/kg HESc
showed a significant increase in latency from minutes 30
to 120 (measures taken every 30min), with no signifi-
cant effect in the following time-points. For the dose of
10 mg/kg HESc, the time effect was extended to up to
150 min, reaching 180 min for the dose of 30 mg/kg
HESc. Importantly, HESc at the doses of 10 and 30mg/
Fig. 1 Effect of previous administration of saline or different doses of HESc (3, 10 or 30mg/kg) on writhing behavior induced by intraperitoneal
administration of 0.4 ml of acetic acid (0.6%) in mice (n = 6 per group). Data are presented as mean ± SEM. #p < 0.05 compared to Saline group;
★p < 0.05compared to HESc 3 mg/kg group. One-way ANOVA followed by Bonferroni test
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kg had a higher effect compared to the dose of 3 mg/kg
on minute 30. Also, 30 mg/kg HESc led to a higher la-
tency to response to thermal stimulus on time 90 com-
pared to all other groups. Thus, with increasing dose
there was not only a more pronounced effect, but also a
dose-dependent effectiveness of HESc across time.
Hypernociception test
Factors used in the two-way repeated measures
ANOVA were time (minutes 30–90), pre-treatment
condition (saline vs HESc) and their interaction.
Two-way repeated measures ANOVA showed a sig-
nificant interaction effect between time and
pre-treatment (Sal vs HESc3, HESc10 or HESc30) fac-
tors [F (8,38) = 3.66; p = 0.003] (n = 5 per group, 5
groups). Bonferroni post hoc test indicated that PGE2
treatment induced a higher difference between basal
and post-treatment mechanical nociceptive thresholds
compared to the Sal-Sal group throughout the session
(Fig. 4). Pre-treatment with HESc was effective in
inhibiting PGE2-induced hypernociception, with 10
and 30 mg/kg HESc being effective at all time-points,
while the dose of 3 mg/kg was only effective at time
90 min.
Rota rod test
Factors used in the two-way repeated measures ANOVA
were time (minutes Basal – 90), treatment condition (sa-
line vs HESc vs diazepam) and their interaction.
Two-way repeated measures ANOVA indicated a signifi-
cant interaction effect between time and treatment (Sal
vs HESc3, HESc10 or HESc30) factors [F (12,150) =
3.02; p = 0.0008] (n = 6 per group, 5 groups). Bonferroni
post hoc test indicated that animals treated with 2mg/
kg diazepam (benzodiazepine, BDZ) showed a significant
reduction in the time spent on the device at 30 and 60
min after treatment, indicating sedative effect with im-
paired balance. Groups treated with different doses of
HESc, on the other hand, did not differ from the Sal
group, showing a lack of sedative effect or impairment
in motor functions.
Fig. 2 Effect of previous administration of saline or different doses of HESc (3, 10 or 30mg/kg) on the acute (a) and inflammatory (b) phases of formalin-
induced nociception (20 μl of 0.2% formalin injection on the plantar surface of right hind paw) in rats (n = 6 per group). Data are presented as mean ± SEM.
#p < 0.05 compared to Saline-Saline group; *p < 0.05 compared to Saline-Formalin group. Two-way repeated measures ANOVA followed by Bonferroni test
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Discussion
In the present study, the hydroalcoholic extract of the
aerial parts of Solidago chilensis Meyen, formulation
most commonly used for therapeutic properties, was
tested in different models of pain and nociception in ro-
dents. HESc exerted antinociceptive effects in models of
inflammatory pain, as expected for an extract with
proven anti-inflammatory action [4]. HESc also had anti-
nociceptive action in models of non-inflammatory pain,
such as nociceptive response to heat or a mechanical
stimulus. Importantly, HESc did not alter time spent in
the rota-rod apparatus. Thus, our data suggest that,
when systemically administered, HESc decreases noci-
ception without inducing a sedative effect.
The antinociceptive investigation in our study was ini-
tiated with the writhing test. This is an unspecific, al-
though very sensitive, model for the evaluation of the
antinociceptive properties of drugs in rodents, with a
high predictive validity [20]. Our results showed a
dose-dependent inhibition of acetic acid-induced writh-
ing behavior by S. chilensis extract (Fig. 1). The nocicep-
tive response in the writhing test has been shown to
Fig. 4 Effect of treatment with saline or HESc (3, 10 or 30mg/kg) on the mechanic hypernociception induced by previous intraplantar injection
of PGE2 in rats (n = 5 per group). Data are presented as mean ± SEM. #p < 0.05 compared to Saline-Saline group; *p < 0.05 compared to Saline-
PGE2 group. Two-way repeated measures ANOVA followed by Bonferroni test
Fig. 3 Antinociceptive effect of saline or HESc (3, 10 or 30mg/kg) in the latency (seconds) to response to thermal stimulus in the hot plate test
across time after treatment in mice (n = 5 per group). Data are presented as mean ± SEM. #p < 0.05 compared to Saline group in the same time-
point; *p < 0.05 compared to HESc 3 mg/kg group in the same time-point; @p < 0.05 compared to all other groups in the same time-point. Two-
way repeated measures ANOVA followed by Bonferroni test
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involve the release of endogenous mediators that stimu-
late nociceptive terminals, such as bradykinin, serotonin,
histamine and prostaglandins [22]. Also, the nociceptive
activity of acetic acid in this model requires the release
of TNF-α and cytokines from local macrophages and
mast cells [23]. In this scenario, the effects observed
with HESc in the writhing test may have been mediated
by direct or indirect inhibition of pro-inflammatory me-
diators or even by central modulation of the nociceptive
transmission.
The antinociceptive action of HESc on the inflamma-
tory phase of the formalin test (Fig. 2b) was an expected
phenomenon. Tamura et al. [4] have demonstrated a sig-
nificant effect of the extract on the mouse ear oedema
induced by Euphorbia milii extract. This effect was asso-
ciated with the mobilization of leukocytes to the inflam-
matory site in the air-pouch model, with significant
anti-inflammatory effects. Tamura and colleagues [4]
also demonstrated the presence of caffeoylquinic and
di-caffeoylquinic acids as major constituents of this ex-
tract. Caffeoylquinic acids decrease the release of hista-
mine from mast cells in vitro [24]. Importantly, Parada
et al. [25] showed that a pretreatment with cromolyn so-
dium (mast cell stabilizer) in the formalin model signifi-
cantly reduced the inflammatory phase of pain. Thus,
HESc-induced inhibition in the inflammatory phase of
the formalin model may have been promoted by a re-
duction in histamine release from mast cells.
Interestingly, HESc also induced a significant reduc-
tion in the non-inflammatory nociceptive phase of pain
in the formalin model (Fig. 2a). Formalin injection has
been shown to cause a direct chemical stimulation in
the spontaneous activity of nociceptive type C fibers
[26]. Terminals of C-fibers are one of the targets of
brain circuits of the pain modulatory system [27]. Thus,
the effects of HESc on the acute (nociceptive) phase of
the formalin test are most likely related to a direct action
on nociceptive terminals, probably due to the release of
excitatory aminoacids, nitric oxide and substance P.
Therefore, we raised the hypothesis that further com-
pounds in the extract (not yet identified) might have sig-
nificant effects on the central transmission of pain,
which takes place in this initial (non-inflammatory)
phase of the formalin test.
To test this hypothesis, we evaluated the effects of HESc
treatment on mice’s thermal response in the hot plate test.
This test is characterized by leading to rapid responses to
noxious stimuli mediated by the activation of nociceptors,
which conduct the impulse to the dorsal horn and then to
cortical centers [28]. C fibers are stimulated by the activa-
tion of vanilloid receptor (VR-1), responsible for detecting
external temperature rise [29]. Thus, if HESc-induced
antinociceptive effects were mediated by central systems
related to the expression of pain, this extract would also
exert antinociceptive effects in the hot plate test. We
found that HESc at all doses significantly increased resist-
ance time in this test. This effect was more pronounced
and lasted longer with an increase in dose (Fig. 3). There-
fore, the antinociceptive effect of HESc in the hot plate
test indicates a possible action of HESc (or its com-
pounds) in higher spinal regions.
To evaluate the effect of the extract of S. chilensis on
hypernociception, we used the model of the electronic
Von Frey. The administration of PGE2 alone induces a
high sensitivity in rodents, with low threshold to pain, as
shown in our control group (PGE2-Sal vs Sal-Sal groups,
Fig. 4). Treatment with HESc led to a dose-dependent
reduction in hypernociception and increase in pain
Fig. 5 Effect of treatment with saline, HESc (3, 10 or 30 mg/kg) or diazepam (BDZ, 2 mg/kg) on the motor coordination of mice (n = 6 per group)
in the rota rod test. Data are presented as the mean ± SEM. *p < 0.05 compared to Saline group. Two-way repeated measures ANOVA followed
by Bonferroni test
Malpezzi-Marinho et al. BMC Complementary and Alternative Medicine           (2019) 19:72 Page 7 of 9
threshold, with hypernociception being abolished by the
highest dose. PGE2 is synthesized in inflammatory sites,
acting as a potent vasodilator and inducing the produc-
tion of several chemo-attractors, such as leukocytes and
pro-inflammatory cytokines [30]. These mediators also
act in acute pain sensitizing nerve terminals of types Aδ
and C nociceptive fibers through EP1 receptors [31].
Thus, the anti-inflammatory mediators present in the
extract of S. chilensis would interfere with the process in
order to reduce the migration of leukocytes to the site of
inflammation, as reported by Tamura et al. [4]. This ef-
fect would also be associated with the possible direct ac-
tion of HESc on central nociceptive terminals.
Together, our results corroborate previous preliminary
findings in humans indicating a possible antinociceptive
action of S. chilensis [16]. Of note, the doses of HESc
used in the present study did not affect motor function
in rodents (Fig. 5), excluding a possible bias of sedative
effects in our study. A previous study from our group
also demonstrated that at the highest dose tested in the
present study (30 mg/kg), no deaths and no adverse ef-
fects were observed in mice following several acute tox-
icity tests [32]. More important, our findings show that
HESc exerts antinociceptive effects in both inflammatory
and non-inflammatory models of nociception and pain.
This suggests a broader action of S. chilensis in pain
management than those specifically related to inflamma-
tory mechanisms. It is important to note, however, that
no positive controls were included in the present study,
limiting the comparison between the antinociceptive ef-
fects of HESc and other standard drugs. Thus, further
studies should address specific compounds of this ex-
tract that might have particular pain-related actions,
possibly indicating new perspectives to clinical practice.
Conclusions
Our data suggest that, when systemically administrated,
HESc decreases nociception without inducing a sedative
effect. Importantly, this effect was observed in both in-
flammatory and non-inflammatory models of pain and
nociception, suggesting a specific non-inflammatory mech-
anism of HESc on pain. Our findings indicate that S. chilen-
sis might be an important adjuvant in pain management.
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